Marizyme, Inc.
MRZM
$0.0003
-$0.0078-96.30%
OTC PK
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | -68.95% | -24.80% | 51.64% | 176.57% | 676.48% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -68.95% | -24.80% | 51.64% | 176.57% | 676.48% |
| Cost of Revenue | -82.22% | -60.24% | 164.33% | 649.54% | 715.26% |
| Gross Profit | -45.24% | 50.71% | -11.17% | 33.31% | 53.96% |
| SG&A Expenses | -2.51% | 75.50% | 133.40% | 104.77% | 18.61% |
| Depreciation & Amortization | -34.72% | -22.66% | -12.10% | -0.05% | 25.72% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -13.63% | 37.57% | 71.09% | 55.13% | 4.92% |
| Operating Income | 11.29% | -40.25% | -71.73% | -52.94% | -1.21% |
| Income Before Tax | 72.33% | 22.92% | -127.26% | -96.38% | -341.18% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 72.33% | 22.92% | -127.26% | -96.38% | -341.18% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 72.33% | 22.92% | -127.26% | -96.38% | -341.18% |
| EBIT | 11.29% | -40.25% | -71.73% | -52.94% | -1.21% |
| EBITDA | 9.78% | -45.30% | -78.60% | -56.61% | -0.59% |
| EPS Basic | 85.43% | 42.96% | -93.86% | -77.31% | -303.27% |
| Normalized Basic EPS | 98.14% | -9.56% | -191.36% | -122.25% | -68.40% |
| EPS Diluted | 85.32% | 42.90% | -93.51% | -77.04% | -303.84% |
| Normalized Diluted EPS | 98.14% | -9.56% | -191.36% | -122.25% | -68.40% |
| Average Basic Shares Outstanding | 162.54% | 118.48% | 67.40% | 11.65% | 7.42% |
| Average Diluted Shares Outstanding | 162.54% | 118.48% | 67.40% | 11.65% | 7.42% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |